NCT01640873View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 19, 2012

Primary Completion Date

December 20, 2012

Study Completion Date

December 20, 2012

Conditions
Type 2 Diabetes
Interventions
DRUG

MK-8655

Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.

DRUG

Placebo

Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01640873 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002) | Biotech Hunter | Biotech Hunter